Identification of F5 as a Prognostic Biomarker in Patients with Gastric Cancer

Table 1

Correlation between OS and clinicopathologic features of GC patients.

Variables	Events/total ()	MST (months)	HR (95% CI)	Logrank value
F5
Low	64/176	38	1
High	80/175	22	1.457 (1.048, 2.025)	0.024
Missing	0
Age (years)
<60	36/108	60	1
≥60	108/240	26	1.549 (1.061, 2.263)	0.022
Missing	3
Gender
Female	100/226	29	1
Male	44/125	35	0.784 (0.55, 1.118)	0.178
Missing	0
Pathological T
T 1/2	28/91	70	1
T 3/4	112/256	26	1.730 (1.138, 2.269)	0.009
Missing	4
Pathological N
N0/N1	70/168	29	1
N2/N3	69/173	29	0.996 (0.714, 1.390)	0.98
Missing	10
Pathological M
M0	13/24	13	1
M1	125/312	35	1.955 (1.103, 3.467)	0.019
Missing	15
TNM stage
Stage I	11/47	73	1
Stage II	34/109	56	1.608 (0.813, 3.182)	<0.001
Stage III	69/147	26	2.435 (1.286, 4.61)
Stage IV	22/35	16	3.789 (1.836, 7.819)
Missing	13
Histologic grade
G1/G2	50/136	43	1
G3	90/206	26	1.366 (0.966, 1.932)	0.077
Missing	9
Radiation therapy
Yes	19/62	NA	1
No	116/266	26	2.322 (1.418, 3.802)	0.001
Missing	23
Targeted molecular therapy
Yes	56/151	43	1
No	78/175	26	1.489 (1.055, 2.1)	0.022
Missing	25
Tumour location
Cardia	36/84	26	1
Body	50/123	28	0.916 (0.596, 1.407)	0.919
Antrum	52/130	35	0.936 (0.611, 1.432)
Missing	14
Histology
Intestinal	64/160	38	1
Diffuse	24/61	60	1.001 (0.625, 1.603)	0.057
Signet ring cell	8/11	13	2.515 (1.204, 5.251)
Others	48/118	26	1.287 (0.884, 1.875)
Missing	1
MSI status
MSS	99/240	28	1
MSI-L	22/51	29	1.263 (0.794, 2.007)	0.225
MSI-H	23/59	35	0.756 (0.48, 1.191)
Missing	1
Cancer status
No	35/206	NA	1
Yes	86/118	17	5.526 (3.695, 8.264)	<0.001
Missing	27

Abbreviations: F5—Coagulation factor V; HR—hazard ratio; MST—median survival time; OS—overall survival; GC—gastric cancer.